Omega-3 Fatty Acid Augmentation of Citalopram Treatment for Patients With Major Depressive Disorder
Open accessThe DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The objective of this study was to explore the efficacy of combination therapy with citalopram plus omega-3 fatty acids versus citalopram plus placebo (olive oil) in the initial treatment of individuals with major depressive disorder (MDD). We hypothesized that combination therapy would lead not only to greater efficacy but also to a more rapid onset of therapeutic response. METHODS: Forty-two subjects participated in this 9-week randomized, masked, placebo-controlled study of combination therapy (two 1 g capsules containing a blend of 900 mg of eicosapentaenoic acid, 200 mg of and docosahexaenoic acid, and 100 mg of other omega-3 fatty acids twice daily plus citalopram) versus monotherapy (two 1 g capsules of olive oil per day plus citalopram) treatment of MDD. RESULTS: The combination therapy demonstrated significantly greater improvement in Hamilton Depression Rating scale scores over time (F = 7.32; df 1,177; P = 0.008) beginning at week 4 (t = -2.48; df 177; P = 0.014). CONCLUSIONS: Combination therapy was more effective than monotherapy in decreasing signs and symptoms of MDD during the 8 weeks of active treatment; however, combination therapy did not seem to enhance the speed of the initial antidepressant response. These findings suggest that there may be an advantage to combining omega-3 fatty acids with a selective serotonin uptake inhibitor in the initial treatment of individuals with MDD. A larger definitive study is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“However, a meta-analysis has shown that rTMS is inferior to ECT with regard to efficacy in TRD 188 .”
From Major depressive disorder (2016) · cites this paper as [188]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.593 · Cited by 20,391 · cited 1×
“The estimated lifetime incidence of MDD in adults in the United States is more than 15%.(3) In 2000, the economic burden of depressive disorders in the United States was an estimated $83.”
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
(1976) · Medical Entomology and Zoology · Cited by 8,899
Development of a Rating Scale for Primary Depressive Illness
HAMILTON, M. (1967) · British Journal of Social and Clinical Psychology · doi:10.1111/j.2044-8260.1967.tb00530.x · Cited by 8,410
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., Rush, A. J., Walters, E. E., & Wang, P. S. (2003) · JAMA · doi:10.1001/jama.289.23.3095 · Cited by 7,988 · cited 1×
“Exclusion criteria were: (1) diagnosis of psychotic disorders including psychotic depression and bipolar disorders; (2) current drug or alcohol abuse or dependence, or history of drug or alcohol abuse or dependence within the previous six months; (3) unstable medical or neurological conditions that were likely to inte…”
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879 · cited 1×
“Exclusion criteria were: (1) diagnosis of psychotic disorders including psychotic depression and bipolar disorders; (2) current drug or alcohol abuse or dependence, or history of drug or alcohol abuse or dependence within the previous six months; (3) unstable medical or neurological conditions that were likely to inte…”
The ESEMeD/MHEDEA 2000 Investigators, Alonso, J., Angermeyer, M. C., Bernert, S., Bruffaerts, R., Brugha, T. S., Bryson, H., de Girolamo, G., de Graaf, R., Demyttenaere, K., et al. (2004) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0047.2004.00327.x · Cited by 1,819 · cited 1×
“Major depressive disorder (MDD) is the most prevalent Axis I disorder and one of the leading causes of disability in the United States and worldwide.(1,2) The estimated lifetime incidence of MDD in adults in the United States is more than 15%.”
The Economic Burden of Depression in the United States: How Did It Change Between 1990 and 2000?
Greenberg, P. E., Kessler, R. C., Birnbaum, H. G., Leong, S. A., Lowe, S. W., Berglund, P. A., & Corey-Lisle, P. K. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n1211 · Cited by 1,280
Nemets, B., Stahl, Z., & Belmaker, R. H. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.3.477 · Cited by 627
Peet, M., & Horrobin, D. F. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.10.913 · Cited by 614
Cited by
Otte, C., Gold, S. M., Penninx, B. W., Pariante, C. M., Etkin, A., Fava, M., Mohr, D. C., & Schatzberg, A. F. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.65 · Cited by 2,269
Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications
Felger, J. C., & Lotrich, F. E. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.04.060 · Cited by 1,180
“Omega-3 fatty acids have increased the antidepressant efficacy of fluoxetine (Jazayeri et al., 2010) and citalopram (Gertsik et al., 2012), and a meta-analysis reported direct antidepressant effects when combining all sources of omega-3 fatty acids (e.g. docosahexaenoic acid, fish oils) (Lin and…”
BackgroundInflamed moods: A review of the interactions between inflammation and mood disorders
Rosenblat, J. D., Cha, D. S., Mansur, R. B., & McIntyre, R. S. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.01.013 · Cited by 609
Dietary patterns and depression risk: a meta-analysis
Li, Y., Lv, M.-R., Wei, Y.-J., Sun, L., Zhang, J.-X., Zhang, H.-G., & Li, B. (2017) · Psychiatry Research · doi:10.1016/j.psychres.2017.04.020 · Cited by 599
“Besides, recent evidence also suggests that adding omega3 fatty acids to antidepressants may improve mood in major depression (Gertsik et al., 2012; Freeman et al., 2006).”
Grosso, G., Pajak, A., Marventano, S., Castellano, S., Galvano, F., Bucolo, C., Drago, F., & Caraci, F. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096905 · Cited by 449
“Compared with previous meta-analyses, the differences of findings may depend on the additional number of RCTs published since the publication of the last study [37,40,53,60,61,66,68,69,84,89,92,94–97,100–102], the increasing number of participants which vary the overall weight of previous studies, the requirement for…”
MethodResult
Metadata
- Authors
- Gertsik, L., Poland, R. E., Bresee, C., & Rapaport, M. H.
- Affiliations
- Cedars-Sinai Medical Center (US)
- Meharry Medical College (US)
- Corresponding author
- Gertsik, Lev
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2012-02
- Volume
- 32
- Issue
- 1
- Pages
- 61-64
- ISSN
- 0271-0749 (ISSN-L)
- PMC
- PMC3375825
- OpenAlex
- W2069184109
- Semantic Scholar
- 1baeee66cc47765e9086c7363078b259186a30f9
- Cited by
- 162
- References
- 37
- Citations by year
- 2025: 5 · 2024: 6 · 2023: 14 · 2022: 6 · 2021: 6 · 2020: 9 · 2019: 13 · 2018: 9 · 2017: 17 · 2016: 21 · 2015: 22 · 2014: 10 · 2013: 19 · 2012: 5
- FWCI
- 10.05
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UL1TR000124)
- National Center for Research Resources (U54RR026140, M01RR000425)
- National Center for Advancing Translational Sciences
- National Institute on Minority Health and Health Disparities (U54MD007593)
- National Center for Complementary and Integrative Health (R21AT001077)
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- omega-3 fatty acids, citalopram, major depressive disorder, combination therapy, eicosapentaenoic acid, docosahexaenoic acid, selective serotonin reuptake inhibitors, antidepressant response, olive oil placebo
- MeSH terms
- Adult, Depressive Disorder, Major, Major Depressive Disorder, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Citalopram, Fatty Acids, Omega-3, Treatment Outcome, Antidepressive Agents, Second-Generation, Dietary Supplements
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Omega-3 Fatty Acid Augmentation of Citalopram Treatment for Patients With Major Depressive Disorder. https://app.cochat.ai/papers/10.1097/jcp.0b013e31823f3b5f
- The paper
- Gertsik, L., Poland, R. E., Bresee, C., & Rapaport, M. H. (2012). Omega-3 Fatty Acid Augmentation of Citalopram Treatment for Patients With Major Depressive Disorder. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0b013e31823f3b5f
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.